Man Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Man Group’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,594	Closed	-$72.7K	–	2205
2024 Q4	$72.7K	Buy	+13,594	New	+$101K	﹤0.01%	1938

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Man Group's CRVS Position: Q1 2025 in Review

Man Group sold out of Corvus Pharmaceuticals (CRVS) in Q1 2025, closing a stake of 13,594 shares — an estimated $72.7K sold.

Man Group first reported a position in CRVS in Q4 2024 and held it in 1 quarter. The position peaked at $72.7K in Q4 2024. 88 funds tracked by Wall St. Rank hold CRVS as of Q1 2025.

Man Group reported no remaining Corvus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Man Group sold 13,594 Corvus Pharmaceuticals shares in Q1 2025, an estimated $72.7K.
Man Group first reported a position in Corvus Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Man Group's Corvus Pharmaceuticals position peaked at $72.7K in Q4 2024.
88 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2025.

Based on Man Group's 13F filing for Q1 2025, filed 15 May 2025.